stockportfolio.pro
Stocks / ENSG vs KRYS
ENSG vs KRYS
The Ensign Group, Inc. and Krystal Biotech, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| The Ensign Group, Inc. (ENSG) | Krystal Biotech, Inc. (KRYS) | |
|---|---|---|
| Market cap | $8.9B | $9.2B |
| Revenue (latest FY) | $5.06B | $389.13M |
| Net income (latest FY) | $343.97M | $204.83M |
| Revenue growth (5y CAGR) | 16.1% | — |
| Net margin | 6.8% | 52.6% |
| Return on equity | 15.4% | 16.8% |
| P/E ratio | 24.6 | 42.0 |
| Dividend yield | 0.2% | — |
| Profitable years (of last 10) | 10 | 3 |
| Positive free cash flow | — | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ENSG — free Open KRYS — freeFrequently asked questions
Which is bigger, ENSG or KRYS?
Krystal Biotech, Inc. is larger by market capitalization — $9.2B versus $8.9B.
Which grows faster, ENSG or KRYS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.